Citizens Jmp Forecasts Strong Price Appreciation for Precigen (NASDAQ:PGEN) Stock

Precigen (NASDAQ:PGEN) had its price target boosted by research analysts at Citizens Jmp from $8.00 to $9.00 in a report released on Thursday,Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s price objective points to a potential upside of 145.23% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the stock. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. HC Wainwright raised their target price on shares of Precigen from $9.00 to $10.00 and gave the company a “buy” rating in a report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Precigen currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $3.67 on Thursday. The business has a fifty day moving average price of $4.08 and a two-hundred day moving average price of $3.98. The stock has a market capitalization of $1.30 billion, a PE ratio of -2.74 and a beta of 1.10. The company has a debt-to-equity ratio of 4.46, a current ratio of 3.09 and a quick ratio of 3.95. Precigen has a fifty-two week low of $1.11 and a fifty-two week high of $5.47.

Precigen (NASDAQ:PGEN) last released its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.09. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.The company had revenue of $4.57 million for the quarter, compared to analyst estimates of $8.29 million. As a group, equities analysts predict that Precigen will post -0.32 earnings per share for the current fiscal year.

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently modified their holdings of PGEN. NBC Securities Inc. acquired a new stake in Precigen in the fourth quarter valued at about $38,000. Mason Investment Advisory Services Inc. acquired a new position in Precigen during the fourth quarter worth about $42,000. Abel Hall LLC bought a new position in shares of Precigen in the fourth quarter worth about $44,000. NewEdge Advisors LLC bought a new position in shares of Precigen in the fourth quarter worth about $45,000. Finally, Asempa Wealth Advisors acquired a new stake in shares of Precigen in the 4th quarter valued at approximately $48,000. 33.51% of the stock is currently owned by institutional investors.

Trending Headlines about Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.